Nab-Paclitaxel Plus Gemcitabine in Locally Advanced Pancreatic Cancer: LAPACT Trial
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On January 14, 2020, Dr. Philip A. Philip and colleagues published the results of the LAPACT Phase 2 clinical trial in The Lancet Gastroenterology & Hepatology. This multicenter, open-label study investigated the role of Nab-paclitaxel (Abraxane) combined with Gemcitabine (Gemzar) as an induction treatment for patients with unresectable locally advanced pancreatic cancer (LAPC).
Study Design: LAPACT Trial
The trial enrolled 106 patients who received Nab-paclitaxel (125 mg/m²) plus Gemcitabine (1,000 mg/m²) on days 1, 8, and 15 of a 28-day cycle for six cycles. Following induction, patients without disease progression or unacceptable toxicity could continue treatment at the investigator's discretion (with chemotherapy, chemoradiotherapy, or surgery).
The primary endpoint was time to treatment failure (TTF).
Key Efficacy Results
- Median Time to Treatment Failure (TTF): 9.0 months.
- Median Progression-Free Survival (PFS): 10.9 months.
- Median Overall Survival (OS): 18.8 months.
- Disease Control Rate (DCR): 77.6%.
- Objective Response Rate (ORR): 33.6%.
Notably, among the 62 patients who completed the induction phase, 17 patients (16% of the total cohort) were able to undergo surgical resection.
Safety Profile
The most common Grade 3 or higher adverse events included:
- Neutropenia: 33%
- Anemia: 11%
- Fatigue: 10%
- Serious events such as pneumonia (5%) and febrile neutropenia (3%) were also reported.
Conclusion
The LAPACT trial results demonstrate that the combination of Nab-paclitaxel and Gemcitabine provides significant antitumor activity and a manageable safety profile in patients with locally advanced pancreatic cancer. These findings support this regimen as a potent induction strategy that may enable subsequent definitive therapies, including surgery, for some patients.
Source: The Lancet Gastroenterology & Hepatology - LAPACT Results
#PancreaticCancer #NabPaclitaxel #Gemcitabine #Gemzar #LAPACTTrial #CancerResearch #LAPC
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4